Extracellular matrix, a hard player in angiogenesis

International Journal of Molecular Sciences

Volumn 17, Issue 11, 2016, Pages

  Mongiat, Maurizio ^a   Andreuzzi, Eva ^a   Tarticchio, Giulia ^a   Paulitti, Alice ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Angiogenesis; Extracellular matrix; Tumor microenvironment

Indexed keywords

ACTIVIN A; ANGIOGENESIS INHIBITOR; BIGLYCAN; CATHEPSIN; CD146 ANTIGEN; CD36 ANTIGEN; CD47 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 15; COLLAGEN TYPE 18; COLLAGEN TYPE 4; DECORIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBRONECTIN; GLYPICAN; HYALURONIC ACID; LAMININ; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PERLECAN; PROTEOCHONDROITIN SULFATE; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; SCATTER FACTOR; STRESS ACTIVATED PROTEIN KINASE; THROMBOSPONDIN; TUMSTATIN; UNINDEXED DRUG; VASCULOTROPIN; CYTOKINE; PROTEIN BINDING; SIGNAL PEPTIDE;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); EXTRACELLULAR MATRIX; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CELLULAR MICROENVIRONMENT; CYTOKINES; EXTRACELLULAR MATRIX; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN BINDING;

EID: 84994717933     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17111822     Document Type: Review

References (248)

1. Ozbek, S.; Balasubramanian, P.G.; Chiquet-Ehrismann, R.; Tucker, R.P.; Adams, J.C. The evolution of extracellular matrix. Mol. Biol. Cell 2010, 21, 4300–4305.
2. Hynes, R.O. The extracellular matrix: Not just pretty fibrils. Science 2009, 326, 1216–1219.
3. Lu, P.; Takai, K.; Weaver, V.M.; Werb, Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol. 2011, 3.
4. Page-McCaw, A.; Ewald, A.J.; Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8, 221–233.
5. Cox, T.R.; Erler, J.T. Remodeling and homeostasis of the extracellular matrix: Implications for fibrotic diseases and cancer. Dis. Model. Mech. 2011, 4, 165–178.
6. Marastoni, S.; Ligresti, G.; Lorenzon, E.; Colombatti, A.; Mongiat, M. Extracellular matrix: A matter of life and death. Connect. Tissue Res. 2008, 49, 203–206.
7. Lu, P.; Weaver, V.M.; Werb, Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol. 2012, 196, 395–406.
8. Sherman-Baust, C.A.; Weeraratna, A.T.; Rangel, L.B.; Pizer, E.S.; Cho, K.R.; Schwartz, D.R.; Shock, T.; Morin, P.J. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003, 3, 377–386.
9. Paszek, M.J.; Zahir, N.; Johnson, K.R.; Lakins, J.N.; Rozenberg, G.I.; Gefen, A.; Reinhart-King, C.A.; Margulies, S.S.; Dembo, M.; Boettiger, D. et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8, 241–254.
10. DuFort, C.C.; Paszek, M.J.; Weaver, V.M. Balancing forces: Architectural control of mechanotransduction. Nat. Rev. Mol. Cell Biol. 2011, 12, 308–319.
11. Marastoni, S.; Andreuzzi, E.; Paulitti, A.; Colladel, R.; Pellicani, R.; Todaro, F.; Schiavinato, A.; Bonaldo, P.; Colombatti, A.; Mongiat, M. EMILIN2 down-modulates the Wnt signalling pathway and suppresses breast cancer cell growth and migration. J. Pathol. 2014, 232, 391–404.
12. Tai, I.T.; Tang, M.J. SPARC in cancer biology: Its role in cancer progression and potential for therapy. Drug Resist. Updates 2008, 11, 231–246.
13. Dhar, A.; Ray, A. The CCN family proteins in carcinogenesis. Exp. Oncol. 2010, 32, 2–9.
14. Reed, C.C.; Waterhouse, A.; Kirby, S.; Kay, P.; Owens, R.T.; McQuillan, D.J.; Iozzo, R.V. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005, 24, 1104–1110.
15. Mongiat, M.; Ligresti, G.; Marastoni, S.; Lorenzon, E.; Doliana, R.; Colombatti, A. Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2. Mol. Cell. Biol. 2007, 27, 7176–7187.
16. Orend, G.; Chiquet-Ehrismann, R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006, 244, 143–163.
17. Folkman, J. Angiogenesis. Annu. Rev. Med. 2006, 57, 1–18.
18. Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 2003, 9, 653–660.
19. Jain, R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005, 307, 58–62.
20. Wong, P.P.; Demircioglu, F.; Ghazaly, E.; Alrawashdeh, W.; Stratford, M.R.; Scudamore, C.L.; Cereser, B.; Crnogorac-Jurcevic, T.; McDonald, S.; Elia, G. et al. Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and Spread. Cancer Cell 2015, 27, 123–137.
21. Andreoli, C.M.; Miller, J.W. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr. Opin. Ophthalmol. 2007, 18, 502–508.
22. Ausprunk, D.H.; Folkman, J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc. Res. 1977, 14, 53–65.
23. Dejana, E.; Languino, L.R.; Polentarutti, N.; Balconi, G.; Ryckewaert, J.J.; Larrieu, M.J.; Donati, M.B.; Mantovani, A.; Marguerie, G. Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J. Clin. Investig. 1985, 75, 11–18.
24. 1 integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am. J. Pathol. 2002, 160, 195–204.
25. Ricard-Blum, S.; Salza, R. Matricryptins and matrikines: Biologically active fragments of the extracellular matrix. Exp. Dermatol. 2014, 23, 457–463.
26. Adams, J.C.; Lawler, J. The thrombospondins. Cold Spring Harb. Perspect. Biol. 2011, 3, a009712.
27. Good, D.J.; Polverini, P.J.; Rastinejad, F.; Le Beau, M.M.; Lemons, R.S.; Frazier, W.A.; Bouck, N.P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 1990, 87, 6624–6628.
28. Tolsma, S.S.; Volpert, O.V.; Good, D.J.; Frazier, W.A.; Polverini, P.J.; Bouck, N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 1993, 122, 497–511.
29. Kyriakides, T.R.; Zhu, Y.H.; Smith, L.T.; Bain, S.D.; Yang, Z.; Lin, M.T.; Danielson, K.G.; Iozzo, R.V.; LaMarca, M.; McKinney, C.E. et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J. Cell Biol. 1998, 140, 419–430.
30. Bleuel, K.; Popp, S.; Fusenig, N.E.; Stanbridge, E.J.; Boukamp, P. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc. Natl. Acad. Sci. USA 1999, 96, 2065–2070.
31. Streit, M.; Riccardi, L.; Velasco, P.; Brown, L.F.; Hawighorst, T.; Bornstein, P.; Detmar, M. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proc. Natl. Acad. Sci. USA 1999, 96, 14888–14893.
32. Streit, M.; Velasco, P.; Brown, L.F.; Skobe, M.; Richard, L.; Riccardi, L.; Lawler, J.; Detmar, M. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am. J. Pathol. 1999, 155, 441–452.
33. Weinstat-Saslow, D.L.; Zabrenetzky, V.S.; VanHoutte, K.; Frazier, W.A.; Roberts, D.D.; Steeg, P.S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994, 54, 6504–6511.
34. Dawson, D.W.; Pearce, S.F.; Zhong, R.; Silverstein, R.L.; Frazier, W.A.; Bouck, N.P. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 1997, 138, 707–717.
35. Dawson, D.W.; Volpert, O.V.; Pearce, S.F.; Schneider, A.J.; Silverstein, R.L.; Henkin, J.; Bouck, N.P. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol. Pharmacol. 1999, 55, 332–338.
36. Yee, K.O.; Connolly, C.M.; Duquette, M.; Kazerounian, S.; Washington, R.; Lawler, J. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res. Treat. 2009, 114, 85–96.
37. Asch, A.S.; Silbiger, S.; Heimer, E.; Nachman, R.L. Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem. Biophys. Res. Commun. 1992, 182, 1208–1217.
38. Jimenez, B.; Volpert, O.V.; Reiher, F.; Chang, L.; Munoz, A.; Karin, M.; Bouck, N. C-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene 2001, 20, 3443–3448.
39. Belotti, D.; Foglieni, C.; Resovi, A.; Giavazzi, R.; Taraboletti, G. Targeting angiogenesis with compounds from the extracellular matrix. Int. J. Biochem. Cell Biol. 2011, 43, 1674–1685.
40. Lawler, P.R.; Lawler, J. Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb. Perspect. Med. 2012, 2, a006627.
41. Resovi, A.; Pinessi, D.; Chiorino, G.; Taraboletti, G. Current understanding of the thrombospondin-1 interactome. Matrix Biol. 2014, 37, 83–91.
42. Taraboletti, G.; Rusnati, M.; Ragona, L.; Colombo, G. Targeting tumor angiogenesis with TSP-1-based compounds: Rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget 2010, 1, 662–673.
43. Zhang, X.; Lawler, J. Thrombospondin-based antiangiogenic therapy. Microvasc. Res. 2007, 74, 90–99.
44. Lawler, J.; Detmar, M. Tumor progression: The effects of thrombospondin-1 and -2. Int. J. Biochem. Cell Biol. 2004, 36, 1038–1045.
45. Haviv, F.; Bradley, M.F.; Kalvin, D.M.; Schneider, A.J.; Davidson, D.J.; Majest, S.M.; McKay, L.M.; Haskell, C.J.; Bell, R.L.; Nguyen, B. et al. Thrombospondin-1 Mimetic Peptide Inhibitors of Angiogenesis and Tumor Growth: Design, Synthesis, and Optimization of Pharmacokinetics and Biological Activities. J. Med. Chem. 2005, 48, 2838–2846.
46. Uronis, H.E.; Cushman, S.M.; Bendell, J.C.; Blobe, G.C.; Morse, M.A.; Nixon, A.B.; Dellinger, A.; Starr, M.D.; Li, H.; Meadows, K. et al. A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med. 2013, 2, 316–324.
47. Peters, J.H.; Chen, G.E.; Hynes, R.O. Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. Cell Adhes. Commun. 1996, 4, 127–148.
48. Astrof, S.; Hynes, R.O. Fibronectins in vascular morphogenesis. Angiogenesis 2009, 12, 165–175.
49. Pedretti, M.; Soltermann, A.; Arni, S.; Weder, W.; Neri, D.; Hillinger, S. Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: Two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer 2009, 64, 28–33.
50. Singh, P.; Carraher, C.; Schwarzbauer, J.E. Assembly of Fibronectin Extracellular Matrix. Annu. Rev. Cell Dev. Biol. 2010, 26, 397–419.
51. Hynes, R.O. Cell-matrix adhesion in vascular development. J. Thromb. Haemost. 2007, 5, 32–40.
52. Hielscher, A.; Ellis, K.; Qiu, C.; Porterfield, J.; Gerecht, S. Fibronectin Deposition Participates in Extracellular Matrix Assembly and Vascular Morphogenesis. PLoS ONE 2016, 11, e0147600.
53. Zhou, X.; Rowe, R.G.; Hiraoka, N.; George, J.P.; Wirtz, D.; Mosher, D.F.; Virtanen, I.; Chernousov, M.A.; Weiss, S.J. Fibronectin fibrillogenesis regulates three-dimensional neovessel formation. Genes Dev. 2008, 22, 1231–1243.
54. Tan, M.H.; Sun, Z.; Opitz, S.L.; Schmidt, T.E.; Peters, J.H.; George, E.L. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 2004, 104, 11–18.
55. Fukuda, T.; Yoshida, N.; Kataoka, Y.; Manabe, R.; Mizuno-Horikawa, Y.; Sato, M.; Kuriyama, K.; Yasui, N.; Sekiguchi, K. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. 2002, 62, 5603–5610.
56. Astrof, S.; Crowley, D.; Hynes, R.O. Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin. Dev. Biol. 2007, 311, 11–24.
57. 1 integrin subfamilies during skin angiogenesis. J. Investig. Dermatol. 2003, 120, 1100–1109.
58. 1 ligation of a GFP*GER sequence and possibly p38 MAPK activation and focal adhesion disassembly. J. Biol. Chem. 2003, 278, 30516–30524.
59. Whelan, M.C.; Senger, D.R. Collagen I initiates endothelial cell morphogenesis by inducing actin polymerization through suppression of cyclic AMP and protein kinase A. J. Biol. Chem. 2003, 278, 327–334.
60. Kamei, M.; Saunders, W.B.; Bayless, K.J.; Dye, L.; Davis, G.E.; Weinstein, B.M. Endothelial tubes assemble from intracellular vacuoles in vivo. Nature 2006, 442, 453–456.
61. Stratman, A.N.; Saunders, W.B.; Sacharidou, A.; Koh, W.; Fisher, K.E.; Zawieja, D.C.; Davis, M.J.; Davis, G.E. Endothelial cell lumen and vascular guidance tunnel formation requires MT1-MMP-dependent proteolysis in 3-dimensional collagen matrices. Blood 2009, 114, 237–247.
62. Davis, G.E.; Senger, D.R. Endothelial extracellular matrix: Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005, 97, 1093–1107.
63. De Smet, F.; Segura, I.; De, B.K.; Hohensinner, P.J.; Carmeliet, P. Mechanisms of vessel branching: Filopodia on endothelial tip cells lead the way. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 639–649.
64. Mundel, T.M.; Kalluri, R. Type IV collagen-derived angiogenesis inhibitors. Microvasc. Res. 2007, 74, 85–89.
65. Sudhakar, A.; Nyberg, P.; Keshamouni, V.G.; Mannam, A.P.; Li, J.; Sugimoto, H.; Cosgrove, D.; Kalluri, R. Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. J. Clin. Investig. 2005, 115, 2801–2810.
66. Kalluri, R. Discovery of type IV collagen non-collagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. Cold Spring Harb. Symp. Quant. Biol. 2002, 67, 255–266.
67. Xu, J.; Rodriguez, D.; Petitclerc, E.; Kim, J.J.; Hangai, M.; Moon, Y.S.; Davis, G.E.; Brooks, P.C. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 2001, 154, 1069–1079.
68. Kim, Y.M.; Jang, J.W.; Lee, O.H.; Yeon, J.; Choi, E.Y.; Kim, K.W.; Lee, S.T.; Kwon, Y.G. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 2000, 60, 5410–5413.
69. Kamphaus, G.D.; Colorado, P.C.; Panka, D.J.; Hopfer, H.; Ramchandran, R.; Torre, A.; Maeshima, Y.; Mier, J.W.; Sukhatme, V.P.; Kalluri, R. Canstatin, a Novel Matrix-derived Inhibitor of Angiogenesis and Tumor Growth. J. Biol. Chem. 2000, 275, 1209–1215.
70. Petitclerc, E.; Boutaud, A.; Prestayko, A.; Xu, J.; Sado, Y.; Ninomiya, Y.; Sarras, M.P., Jr.; Hudson, B.G.; Brooks, P.C. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem. 2000, 275, 8051–8061.
71. Aikio, M.; Alahuhta, I.; Nurmenniemi, S.; Suojanen, J.; Palovuori, R.; Teppo, S.; Sorsa, T.; Lopez-Otin, C.; Pihlajaniemi, T.; Salo, T. et al. Arresten, a collagen-derived angiogenesis inhibitor, suppresses invasion of squamous cell carcinoma. PLoS ONE 2012, 7, e51044.
72. He, G.A.; Luo, J.X.; Zhang, T.Y.; Wang, F.Y.; Li, R.F. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth. Biochem. Biophys. Res. Commun. 2003, 312, 801–805.
73. Hwang-Bo, J.; Yoo, K.H.; Park, J.H.; Jeong, H.S.; Chung, I.S. Recombinant canstatin inhibits angiopoietin-1-induced angiogenesis and lymphangiogenesis. Int. J. Cancer 2012, 131, 298–309.
74. 5 integrins. Cancer Res. 2005, 65, 4353–4361.
75. Panka, D.J.; Mier, J.W. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J. Biol. Chem. 2003, 278, 37632–37636.
76. Maeshima, Y.; Sudhakar, A.; Lively, J.C.; Ueki, K.; Kharbanda, S.; Kahn, C.R.; Sonenberg, N.; Hynes, R.O.; Kalluri, R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295, 140–143.
77. Xie, L.; Duncan, M.B.; Pahler, J.; Sugimoto, H.; Martino, M.; Lively, J.; Mundel, T.; Soubasakos, M.; Rubin, K.; Takeda, T. et al. Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc. Natl. Acad. Sci. USA 2011, 108, 9939–9944.
78. Myers, J.C.; Dion, A.S.; Abraham, V.; Amenta, P.S. Type XV collagen exhibits a widespread distribution in human tissues but a distinct localization in basement membrane zones. Cell Tissue Res. 1996, 286, 493–505.
79. Muragaki, Y.; Abe, N.; Ninomiya, Y.; Olsen, B.R.; Ooshima, A. The human α 1(XV) collagen chain contains a large amino-terminal non-triple helical domain with a tandem repeat structure and homology to α 1(XVIII) collagen. J. Biol. Chem. 1994, 269, 4042–4046.
80. Ramchandran, R.; Dhanabal, M.; Volk, R.; Waterman, M.J.; Segal, M.; Lu, H.; Knebelmann, B.; Sukhatme, V.P. Antiangiogenic activity of restin, NC10 domain of human collagen XV: Comparison to endostatin. Biochem. Biophys. Res. Commun. 1999, 255, 735–739.
81. John, H.; Radtke, K.; Standker, L.; Forssmann, W.G. Identification and characterization of novel endogenous proteolytic forms of the human angiogenesis inhibitors restin and endostatin. Biochim. Biophys. Acta 2005, 1747, 161–170.
82. Eklund, L.; Piuhola, J.; Komulainen, J.; Sormunen, R.; Ongvarrasopone, C.; Fassler, R.; Muona, A.; Ilves, M.; Ruskoaho, H.; Takala, T.E. et al. Lack of type XV collagen causes a skeletal myopathy and cardiovascular defects in mice. Proc. Natl. Acad. Sci. USA 2001, 98, 1194–1199.
83. O’Reilly, M.S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W.S.; Flynn, E.; Birkhead, J.R.; Olsen, B.R.; Folkman, J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88, 277–285.
84. Ferreras, M.; Felbor, U.; Lenhard, T.; Olsen, B.R.; Delaisse, J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000, 486, 247–251.
85. Lee, S.J.; Jang, J.W.; Kim, Y.M.; Lee, H.I.; Jeon, J.Y.; Kwon, Y.G.; Lee, S.T. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett. 2002, 519, 147–152.
86. Chang, J.H.; Gabison, E.E.; Kato, T.; Azar, D.T. Corneal neovascularization. Curr. Opin. Ophthalmol. 2001, 12, 242–249.
87. Ling, Y.; Yang, Y.; Lu, N.; You, Q.D.; Wang, S.; Gao, Y.; Chen, Y.; Guo, Q.L. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem. Biophys. Res. Commun. 2007, 361, 79–84.
88. Kim, H.S.; Lim, S.J.; Park, Y.K. Anti-angiogenic factor endostatin in osteosarcoma. APMIS 2009, 117, 716–723.
89. Chen, Y.; Huang, H.; Yao, C.; Su, F.; Guan, W.; Yan, S.; Ni, Z. Antitumor activity of combined endostatin and thymidine kinase gene therapy in C6 glioma models. Cancer Med. 2016, 5, 2477–2486.
90. Ferician, O.; Cimpean, A.M.; Avram, S.; Raica, M. Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane. Anticancer Res. 2015, 35, 6521–6528.
91. Guan, Y.; Li, A.; Xiao, W.; Liu, S.; Chen, B.; Lu, T.; Zhao, C.; Han, F. The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma. Oncotarget 2015, 6, 33926–33934.
92. Li, W.; Zhao, X.; Du, B.; Li, X.; Liu, S.; Yang, X.Y.; Ding, H.; Yang, W.; Pan, F.; Wu, X. et al. Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy. Sci. Rep. 2016, 6, 30619.
93. Sun, X.J.; Deng, Q.H.; Yu, X.M.; Ji, Y.L.; Zheng, Y.D.; Jiang, H.; Xu, Y.P.; Ma, S.L. A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer. BMC Cancer 2016, 16, 266.
94. Kulke, M.H.; Bergsland, E.K.; Ryan, D.P.; Enzinger, P.C.; Lynch, T.J.; Zhu, A.X.; Meyerhardt, J.A.; Heymach, J.V.; Fogler, W.E.; Sidor, C. et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2006, 24, 3555–3561.
95. Cui, C.; Mao, L.; Chi, Z.; Si, L.; Sheng, X.; Kong, Y.; Li, S.; Lian, B.; Gu, K.; Tao, M. et al. A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol. Ther. 2013, 21, 1456–1463.
96. Durbeej, M. Laminins. Cell Tissue Res. 2010, 339, 259–268.
97. Boroujerdi, A.; Welser-Alves, J.V.; Milner, R. Matrix metalloproteinase-9 mediates post-hypoxic vascular pruning of cerebral blood vessels by degrading laminin and claudin-5. Angiogenesis 2015, 18, 255–264.
98. Khan, K.M.; Falcone, D.J. Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression. J. Biol. Chem. 1997, 272, 8270–8275.
99. Yousif, L.F.; di Russo, J.; Sorokin, L. Laminin isoforms in endothelial and perivascular basement membranes. Cell Adhes. Migr. 2013, 7, 101–110.
100. Sixt, M.; Engelhardt, B.; Pausch, F.; Hallmann, R.; Wendler, O.; Sorokin, L.M. Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis. J. Cell Biol. 2001, 153, 933–946.
101. Gonzalez, A.M.; Gonzales, M.; Herron, G.S.; Nagavarapu, U.; Hopkinson, S.B.; Tsuruta, D.; Jones, J.C. Complex interactions between the laminin α4 subunit and integrins regulate endothelial cell behavior in vitro and angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 2002, 99, 16075–16080.
102. Wragg, J.W.; Finnity, J.P.; Anderson, J.A.; Ferguson, H.J.; Porfiri, E.; Bhatt, R.I.; Murray, P.G.; Heath, V.L.; Bicknell, R. MCAM and LAMA4 Are Highly Enriched in Tumor Blood Vessels of Renal Cell Carcinoma and Predict Patient Outcome. Cancer Res. 2016, 76, 2314–2326.
103. Estrach, S.; Cailleteau, L.; Franco, C.A.; Gerhardt, H.; Stefani, C.; Lemichez, E.; Gagnoux-Palacios, L.; Meneguzzi, G.; Mettouchi, A. Laminin-binding integrins induce Dll4 expression and Notch signaling in endothelial cells. Circ. Res. 2011, 109, 172–182.
104. Hibino, S.; Shibuya, M.; Hoffman, M.P.; Engbring, J.A.; Hossain, R.; Mochizuki, M.; Kudoh, S.; Nomizu, M.; Kleinman, H.K. Laminin α5 chain metastasis- and angiogenesis-inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44. Cancer Res. 2005, 65, 10494–10501.
105. Thyboll, J.; Kortesmaa, J.; Cao, R.; Soininen, R.; Wang, L.; Iivanainen, A.; Sorokin, L.; Risling, M.; Cao, Y.; Tryggvason, K. Deletion of the laminin α4 chain leads to impaired microvessel maturation. Mol. Cell. Biol. 2002, 22, 1194–1202.
106. Di Russo, J.; Hannocks, M.J.; Luik, A.L.; Song, J.; Zhang, X.; Yousif, L.; Aspite, G.; Hallmann, R.; Sorokin, L. Vascular laminins in physiology and pathology. Matrix Biol. 2016.
107. 1 controls VE-cadherin localization and blood vessel stability. Nat. Commun. 2015, 6, 6429.
108. Stamati, K.; Priestley, J.V.; Mudera, V.; Cheema, U. Laminin promotes vascular network formation in 3D in vitro collagen scaffolds by regulating VEGF uptake. Exp. Cell Res. 2014, 327, 68–77.
109. Seano, G.; Chiaverina, G.; Gagliardi, P.A.; di Blasio, L.; Puliafito, A.; Bouvard, C.; Sessa, R.; Tarone, G.; Sorokin, L.; Helley, D. et al. Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis. Nat. Cell Biol. 2014, 16, 931–938.
110. Theocharis, A.D.; Skandalis, S.S.; Tzanakakis, G.N.; Karamanos, N.K. Proteoglycans in health and disease: Novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010, 277, 3904–3923.
111. Afratis, N.; Gialeli, C.; Nikitovic, D.; Tsegenidis, T.; Karousou, E.; Theocharis, A.D.; Pavao, M.S.; Tzanakakis, G.N.; Karamanos, N.K. Glycosaminoglycans: Key players in cancer cell biology and treatment. FEBS J. 2012, 279, 1177–1197.
112. Iozzo, R.V.; Sanderson, R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 2011, 15, 1013–1031.
113. Chiodelli, P.; Bugatti, A.; Urbinati, C.; Rusnati, M. Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: Biological implications and therapeutical use. Molecules 2015, 20, 6342–6388.
114. Iozzo, R.V.; Schaefer, L. Proteoglycan form and function: A comprehensive nomenclature of proteoglycans. Matrix Biol. 2015, 42, 11–55.
115. Theocharis, A.D.; Skandalis, S.S.; Neill, T.; Multhaupt, H.A.; Hubo, M.; Frey, H.; Gopal, S.; Gomes, A.; Afratis, N.; Lim, H.C.; et al. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim. Biophys. Acta 2015, 1855, 276–300.
116. Sanderson, R.D.; Yang, Y.; Suva, L.J.; Kelly, T. Heparan sulfate proteoglycans and heparanase—Partners in osteolytic tumor growth and metastasis. Matrix Biol. 2004, 23, 341–352.
117. Ritchie, J.P.; Ramani, V.C.; Ren, Y.; Naggi, A.; Torri, G.; Casu, B.; Penco, S.; Pisano, C.; Carminati, P.; Tortoreto, M. et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin. Cancer Res. 2011, 17, 1382–1393.
118. Filmus, J.; Selleck, S.B. Glypicans: Proteoglycans with a surprise. J. Clin. Investig. 2001, 108, 497–501.
119. Suhovskih, A.V.; Aidagulova, S.V.; Kashuba, V.I.; Grigorieva, E.V. Proteoglycans as potential microenvironmental biomarkers for colon cancer. Cell Tissue Res. 2015, 361, 833–844.
120. Baghy, K.; Tatrai, P.; Regos, E.; Kovalszky, I. Proteoglycans in liver cancer. World J. Gastroenterol. 2016, 22, 379–393.
121. Murdoch, A.D.; Dodge, G.R.; Cohen, I.; Tuan, R.S.; Iozzo, R.V. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J. Biol. Chem. 1992, 267, 8544–8557.
122. Iozzo, R.V.; Cohen, I.R.; Grassel, S.; Murdoch, A.D. The biology of perlecan: The multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem. J. 1994, 302, 625–639.
123. Farach-Carson, M.C.; Carson, D.D. Perlecan-a multifunctional extracellular proteoglycan scaffold. Glycobiology 2007, 17, 897–905.
124. Murdoch, A.D.; Liu, B.; Schwarting, R.; Tuan, R.S.; Iozzo, R.V. Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J. Histochem. Cytochem. 1994, 42, 239–249.
125. Handler, M.; Yurchenco, P.D.; Iozzo, R.V. Developmental expression of perlecan during murine embryogenesis. Dev. Dyn. 1997, 210, 130–145.
126. Whitelock, J.M.; Melrose, J.; Iozzo, R.V. Diverse cell signaling events modulated by perlecan. Biochemistry 2008, 47, 11174–11183.
127. Mongiat, M.; Taylor, K.; Otto, J.; Aho, S.; Uitto, J.; Whitelock, J.M.; Iozzo, R.V. The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7. J. Biol. Chem. 2000, 275, 7095–7100.
128. Mongiat, M.; Otto, J.; Oldershaw, R.; Ferrer, F.; Sato, J.D.; Iozzo, R.V. Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J. Biol. Chem. 2001, 276, 10263–10271.
129. Mongiat, M.; Fu, J.; Oldershaw, R.; Greenhalgh, R.; Gown, A.M.; Iozzo, R.V. Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J. Biol. Chem. 2003, 278, 17491–17499.
130. Gonzalez, E.M.; Mongiat, M.; Slater, S.J.; Baffa, R.; Iozzo, R.V. A novel interaction between perlecan protein core and progranulin: Potential effects on tumor growth. J. Biol. Chem. 2003, 278, 38113–38116.
131. Li, S.; Shimono, C.; Norioka, N.; Nakano, I.; Okubo, T.; Yagi, Y.; Hayashi, M.; Sato, Y.; Fujisaki, H.; Hattori, S. et al. Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity. J. Biol. Chem. 2010, 285, 36645–36655.
132. Poluzzi, C.; Iozzo, R.V.; Schaefer, L. Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers. Adv. Drug Deliv. Rev. 2016, 97, 156–173.
133. Sharma, B.; Handler, M.; Eichstetter, I.; Whitelock, J.M.; Nugent, M.A.; Iozzo, R.V. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J. Clin. Investig. 1998, 102, 1599–1608.
134. Iozzo, R.V.; San Antonio, J.D. Heparan sulfate proteoglycans: Heavy hitters in the angiogenesis arena. J. Clin. Investig. 2001, 108, 349–355.
135. Zhou, Z.; Wang, J.; Cao, R.; Morita, H.; Soininen, R.; Chan, K.M.; Liu, B.; Cao, Y.; Tryggvason, K. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res. 2004, 64, 4699–4702.
136. Aviezer, D.; Hecht, D.; Safran, M.; Eisinger, M.; David, G.; Yayon, A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994, 79, 1005–1013.
137. Ghiselli, G.; Eichstetter, I.; Iozzo, R.V. A role for the perlecan protein core in the activation of the keratinocyte growth factor receptor. Biochem. J. 2001, 359, 153–163.
138. Murakami, M.; Simons, M. Fibroblast growth factor regulation of neovascularization. Curr. Opin. Hematol. 2008, 15, 215–220.
139. Zoeller, J.J.; Whitelock, J.M.; Iozzo, R.V. Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol. 2009, 28, 284–291.
140. Chuang, C.Y.; Lord, M.S.; Melrose, J.; Rees, M.D.; Knox, S.M.; Freeman, C.; Iozzo, R.V.; Whitelock, J.M. Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. Biochemistry 2010, 49, 5524–5532.
141. Muthusamy, A.; Cooper, C.R.; Gomes, R.R., Jr. Soluble perlecan domain I enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells. BMC Biochem. 2010, 11, 43.
142. Lord, M.S.; Chuang, C.Y.; Melrose, J.; Davies, M.J.; Iozzo, R.V.; Whitelock, J.M. The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling. Matrix Biol. 2014, 35, 112–122.
143. Whitelock, J.M.; Murdoch, A.D.; Iozzo, R.V.; Underwood, P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 1996, 271, 10079–10086.
144. Marchisone, C.; Del Grosso, F.; Masiello, L.; Prat, M.; Santi, L.; Noonan, D.M. Phenotypic alterations in Kaposi's sarcoma cells by antisense reduction of perlecan. Pathol. Oncol. Res. 2000, 6, 10–17.
145. Chang, J.W.; Kang, U.B.; Kim, D.H.; Yi, J.K.; Lee, J.W.; Noh, D.Y.; Lee, C.; Yu, M.H. Identification of circulating endorepellin LG3 fragment: Potential use as a serological biomarker for breast cancer. Proteom. Clin. Appl. 2008, 2, 23–32.
146. Kawahara, R.; Granato, D.C.; Carnielli, C.M.; Cervigne, N.K.; Oliveria, C.E.; Rivera, C.; Yokoo, S.; Fonseca, F.P.; Lopes, M.; Santos-Silva, A.R. et al. Agrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma. PLoS ONE 2014, 9, e115004.
147. Grindel, B.; Li, Q.; Arnold, R.; Petros, J.; Zayzafoon, M.; Muldoon, M.; Stave, J.; Chung, L.W.; Farach-Carson, M.C. Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: Tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients. Oncotarget 2016, 7, 10433–10447.
148. Mongiat, M.; Sweeney, S.M.; San Antonio, J.D.; Fu, J.; Iozzo, R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 2003, 278, 4238–4249.
149. 1 integrin. J. Cell Biol. 2004, 166, 97–109.
150. Bix, G.; Castello, R.; Burrows, M.; Zoeller, J.J.; Weech, M.; Iozzo, R.A.; Cardi, C.; Thakur, M.L.; Barker, C.A.; Camphausen, K. et al. Endorepellin in vivo: Targeting the tumor vasculature and retarding cancer growth and metabolism. J. Natl. Cancer Inst. 2006, 98, 1634–1646.
151. 1 is the required receptor for endorepellin angiostatic activity. J. Biol. Chem. 2008, 283, 2335–2343.
152. Nystrom, A.; Shaik, Z.P.; Gullberg, D.; Krieg, T.; Eckes, B.; Zent, R.; Pozzi, A.; Iozzo, R.V. Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity. Blood 2009, 114, 4897–4906.
153. Goyal, A.; Poluzzi, C.; Willis, C.D.; Smythies, J.; Shellard, A.; Neill, T.; Iozzo, R.V. Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: Transcriptional repression of hypoxia-inducible factor 1α and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation. J. Biol. Chem. 2012, 287, 43543–43556.
154. 1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): A dual receptor antagonism. J. Biol. Chem. 2011, 286, 25947–25962.
155. Douglass, S.; Goyal, A.; Iozzo, R.V. The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy. Connect. Tissue Res. 2015, 56, 381–391.
156. Poluzzi, C.; Casulli, J.; Goyal, A.; Mercer, T.J.; Neill, T.; Iozzo, R.V. Endorepellin evokes autophagy in endothelial cells. J. Biol. Chem. 2014, 289, 16114–16128.
157. Goyal, A.; Gubbiotti, M.A.; Chery, D.R.; Han, L.; Iozzo, R.V. Endorepellin-evoked autophagy contributes to angiostasis. J. Biol. Chem. 2016.
158. Sofeu Feugaing, D.D.; Gotte, M.; Viola, M. More than matrix: The multifaceted role of decorin in cancer. Eur. J. Cell Biol. 2013, 92, 1–11.
159. Jarvelainen, H.; Vernon, R.B.; Gooden, M.D.; Francki, A.; Lara, S.; Johnson, P.Y.; Kinsella, M.G.; Sage, E.H.; Wight, T.N. Overexpression of decorin by rat arterial smooth muscle cells enhances contraction of type I collagen in vitro. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 67–72.
160. Kalamajski, S.; Oldberg, A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol. 2010, 29, 248–253.
161. Reese, S.P.; Underwood, C.J.; Weiss, J.A. Effects of decorin proteoglycan on fibrillogenesis, ultrastructure, and mechanics of type I collagen gels. Matrix Biol. 2013, 32, 414–423.
162. Morcavallo, A.; Buraschi, S.; Xu, S.Q.; Belfiore, A.; Schaefer, L.; Iozzo, R.V.; Morrione, A. Decorin differentially modulates the activity of insulin receptor isoform A ligands. Matrix Biol. 2014, 35, 82–90.
163. Mohan, R.R.; Tovey, J.C.; Sharma, A.; Schultz, G.S.; Cowden, J.W.; Tandon, A. Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS ONE 2011, 6, e26432.
164. Scott, R.A.; Panitch, A. Decorin mimic regulates platelet-derived growth factor and interferon-gamma stimulation of vascular smooth muscle cells. Biomacromolecules 2014, 15, 2090–2103.
165. Jarvelainen, H.; Sainio, A.; Wight, T.N. Pivotal role for decorin in angiogenesis. Matrix Biol. 2015, 43, 15–26.
166. Imai, K.; Hiramatsu, A.; Fukushima, D.; Pierschbacher, M.D.; Okada, Y. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release. Biochem. J. 1997, 322, 809–814.
167. Boivin, W.A.; Shackleford, M.; Vanden Hoek, A.; Zhao, H.; Hackett, T.L.; Knight, D.A.; Granville, D.J. Granzyme B cleaves decorin, biglycan and soluble βglycan, releasing active transforming growth factor-β1. PLoS ONE 2012, 7, e33163.
168. Neill, T.; Schaefer, L.; Iozzo, R.V. Decorin as a multivalent therapeutic agent against cancer. Adv. Drug Deliv. Rev. 2016, 97, 174–185.
169. Neill, T.; Painter, H.; Buraschi, S.; Owens, R.T.; Lisanti, M.P.; Schaefer, L.; Iozzo, R.V. Decorin antagonizes the angiogenic network: Concurrent inhibition of Met, hypoxia inducible factor 1α, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J. Biol. Chem. 2012, 287, 5492–5506.
170. Goyal, A.; Neill, T.; Owens, R.T.; Schaefer, L.; Iozzo, R.V. Decorin activates AMPK, an energy sensor kinase, to induce autophagy in endothelial cells. Matrix Biol. 2014, 35, 42–50.
171. Buraschi, S.; Neill, T.; Goyal, A.; Poluzzi, C.; Smythies, J.; Owens, R.T.; Schaefer, L.; Torres, A.; Iozzo, R.V. Decorin causes autophagy in endothelial cells via Peg3. Proc. Natl. Acad. Sci. USA 2013, 110, E2582–E2591.
172. Gubbiotti, M.A.; Iozzo, R.V. Proteoglycans regulate autophagy via outside-in signaling: An emerging new concept. Matrix Biol. 2015, 48, 6–13.
173. Schonherr, E.; Sunderkotter, C.; Schaefer, L.; Thanos, S.; Grassel, S.; Oldberg, A.; Iozzo, R.V.; Young, M.F.; Kresse, H. Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. J. Vasc. Res. 2004, 41, 499–508.
174. Jarvelainen, H.; Puolakkainen, P.; Pakkanen, S.; Brown, E.L.; Hook, M.; Iozzo, R.V.; Sage, E.H.; Wight, T.N. A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen. 2006, 14, 443–452.
175. Grant, D.S.; Yenisey, C.; Rose, R.W.; Tootell, M.; Santra, M.; Iozzo, R.V. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 2002, 21, 4765–4777.
176. Berendsen, A.D.; Pinnow, E.L.; Maeda, A.; Brown, A.C.; McCartney-Francis, N.; Kram, V.; Owens, R.T.; Robey, P.G.; Holmbeck, K.; de Castro, L.F. et al. Biglycan modulates angiogenesis and bone formation during fracture healing. Matrix Biol. 2014, 35, 223–231.
177. Myren, M.; Kirby, D.J.; Noonan, M.L.; Maeda, A.; Owens, R.T.; Ricard-Blum, S.; Kram, V.; Kilts, T.M.; Young, M.F. Biglycan potentially regulates angiogenesis during fracture repair by altering expression and function of endostatin. Matrix Biol. 2016, 52–54, 141–150.
178. Xing, X.; Gu, X.; Ma, T.; Ye, H. Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer. Tumour Biol. 2015, 36, 1773–1780.
179. Barbouri, D.; Afratis, N.; Gialeli, C.; Vynios, D.H.; Theocharis, A.D.; Karamanos, N.K. Syndecans as modulators and potential pharmacological targets in cancer progression. Front. Oncol. 2014, 4, 4.
180. 3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis. FEBS J. 2013, 280, 2194–2206.
181. Lamorte, S.; Ferrero, S.; Aschero, S.; Monitillo, L.; Bussolati, B.; Omede, P.; Ladetto, M.; Camussi, G. Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Leukemia 2012, 26, 1081–1090.
182. Jing, Z.; Wei-Jie, Y.; Yi-Feng, Z.G.; Jing, H. Downregulation of Syndecan-1 induce glomerular endothelial cell dysfunction through modulating internalization of VEGFR-2. Cell Signal. 2016, 28, 826–837.
183. Maeda, T.; Desouky, J.; Friedl, A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006, 25, 1408–1412.
184. Noguer, O.; Villena, J.; Lorita, J.; Vilaro, S.; Reina, M. Syndecan-2 downregulation impairs angiogenesis in human microvascular endothelial cells. Exp. Cell Res. 2009, 315, 795–808.
185. Purushothaman, A.; Uyama, T.; Kobayashi, F.; Yamada, S.; Sugahara, K.; Rapraeger, A.C.; Sanderson, R.D. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010, 115, 2449–2457.
186. De Rossi, G.; Evans, A.R.; Kay, E.; Woodfin, A.; McKay, T.R.; Nourshargh, S.; Whiteford, J.R. Shed syndecan-2 inhibits angiogenesis. J. Cell Sci. 2014, 127, 4788–4799.
187. Rodriguez-Manzaneque, J.C.; Carpizo, D.; Plaza-Calonge, M.C.; Torres-Collado, A.X.; Thai, S.N.; Simons, M.; Horowitz, A.; Iruela-Arispe, M.L. Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion. Int. J. Biochem. Cell Biol. 2009, 41, 800–810.
188. Li, R.; Xie, J.; Wu, H.; Li, G.; Chen, J.; Chen, Q.; Wang, L.; Xu, B. Syndecan-4 shedding impairs macrovascular angiogenesis in diabetes mellitus. Biochem. Biophys. Res. Commun. 2016, 474, 15–21.
189. Aikawa, T.; Whipple, C.A.; Lopez, M.E.; Gunn, J.; Young, A.; Lander, A.D.; Korc, M. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J. Clin. Investig. 2008, 118, 89–99.
190. Qiao, D.; Meyer, K.; Mundhenke, C.; Drew, S.A.; Friedl, A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis. J. Biol. Chem. 2003, 278, 16045–16053.
191. Fico, A.; Maina, F.; Dono, R. Fine-tuning of cell signaling by glypicans. Cell. Mol. Life Sci. 2011, 68, 923–929.
192. Monteforte, A.J.; Lam, B.; Das, S.; Mukhopadhyay, S.; Wright, C.S.; Martin, P.E.; Dunn, A.K.; Baker, A.B. Glypican-1 nanoliposomes for potentiating growth factor activity in therapeutic angiogenesis. Biomaterials 2016, 94, 45–56.
193. Naito, Z. Role of the small leucine-rich proteoglycan (SLRP) family in pathological lesions and cancer cell growth. J. Nippon Med. Sch. 2005, 72, 137–145.
194. D'Onofrio, M.F.; Brezillon, S.; Baranek, T.; Perreau, C.; Roughley, P.J.; Maquart, F.X.; Wegrowski, Y. Identification of β1 integrin as mediator of melanoma cell adhesion to lumican. Biochem. Biophys. Res. Commun. 2008, 365, 266–272.
195. Albig, A.R.; Roy, T.G.; Becenti, D.J.; Schiemann, W.P. Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: Identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis 2007, 10, 197–216.
196. 1 receptor activity and downregulating MMP-14 expression. Thromb. Res. 2011, 128, 452–457.
197. Nikitovic, D.; Papoutsidakis, A.; Karamanos, N.K.; Tzanakakis, G.N. Lumican affects tumor cell functions, tumor-ECM interactions, angiogenesis and inflammatory response. Matrix Biol. 2014, 35, 206–214.
198. Williams, K.E.; Fulford, L.A.; Albig, A.R. Lumican reduces tumor growth via induction of fas-mediated endothelial cell apoptosis. Cancer Microenviron. 2010, 4, 115–126.
199. Chanmee, T.; Ontong, P.; Itano, N. Hyaluronan: A modulator of the tumor microenvironment. Cancer Lett. 2016, 375, 20–30.
200. Slevin, M.; Kumar, S.; Gaffney, J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J. Biol. Chem. 2002, 277, 41046–41059.
201. Toole, B.P. Hyaluronan: From extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4, 528–539.
202. Savani, R.C.; Cao, G.; Pooler, P.M.; Zaman, A.; Zhou, Z.; DeLisser, H.M. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J. Biol. Chem. 2001, 276, 36770–36778.
203. Slevin, M.; Krupinski, J.; Gaffney, J.; Matou, S.; West, D.; Delisser, H.; Savani, R.C.; Kumar, S. Hyaluronan-mediated angiogenesis in vascular disease: Uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol. 2007, 26, 58–68.
204. Gao, F.; Yang, C.X.; Mo, W.; Liu, Y.W.; He, Y.Q. Hyaluronan oligosaccharides are potential stimulators to angiogenesis via RHAMM mediated signal pathway in wound healing. Clin. Investig. Med. 2008, 31, E106–E116.
205. Wang, Y.; Han, G.; Guo, B.; Huang, J. Hyaluronan oligosaccharides promote diabetic wound healing by increasing angiogenesis. Pharmacol. Rep. 2016, 68, 1126–1132.
206. Olivares, C.N.; Alaniz, L.D.; Menger, M.D.; Baranao, R.I.; Laschke, M.W.; Meresman, G.F. Inhibition of Hyaluronic Acid Synthesis Suppresses Angiogenesis in Developing Endometriotic Lesions. PLoS ONE 2016, 11, e0152302.
207. Litwiniuk, M.; Krejner, A.; Speyrer, M.S.; Gauto, A.R.; Grzela, T. Hyaluronic Acid in Inflammation and Tissue Regeneration. Wounds 2016, 28, 78–88.
208. West, D.C.; Kumar, S. The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp. Cell Res. 1989, 183, 179–196.
209. Bollyky, P.L.; Lord, J.D.; Masewicz, S.A.; Evanko, S.P.; Buckner, J.H.; Wight, T.N.; Nepom, G.T. Cutting edge: High molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells. J. Immunol. 2007, 179, 744–747.
210. Fuchs, K.; Hippe, A.; Schmaus, A.; Homey, B.; Sleeman, J.P.; Orian-Rousseau, V. Opposing effects of high- and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44. Cell Death Dis. 2013, 4, e819.
211. Koyama, H.; Hibi, T.; Isogai, Z.; Yoneda, M.; Fujimori, M.; Amano, J.; Kawakubo, M.; Kannagi, R.; Kimata, K.; Taniguchi, S. et al. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: Possible involvement of versican/PG-M. Am. J. Pathol. 2007, 170, 1086–1099.
212. Singleton, P.A. Hyaluronan regulation of endothelial barrier function in cancer. Adv. Cancer Res. 2014, 123, 191–209.
213. Doliana, R.; Canton, A.; Bucciotti, F.; Mongiat, M.; Bonaldo, P.; Colombatti, A. Structure, chromosomal localization, and promoter analysis of the human elastin microfibril interfase located proteIN (EMILIN) gene. J. Biol. Chem. 2000, 275, 785–792.
214. Mongiat, M.; Mungiguerra, G.; Bot, S.; Mucignat, M.T.; Giacomello, E.; Doliana, R.; Colombatti, A. Self-assembly and supramolecular organization of EMILIN. J. Biol. Chem. 2000, 275, 25471–25480.
215. Colombatti, A.; Spessotto, P.; Doliana, R.; Mongiat, M.; Bressan, G.M.; Esposito, G. The EMILIN/Multimerin family. Front. Immunol. 2011, 2, 93.
216. Bot, S.; Andreuzzi, E.; Capuano, A.; Schiavinato, A.; Colombatti, A.; Doliana, R. Multiple-interactions among EMILIN1 and EMILI. Matrix Biol. 2015, 41, 44–55.
217. Jeimy, S.B.; Tasneem, S.; Cramer, E.M.; Hayward, C.P. Multimerin 1. Platelets 2008, 19, 83–95.
218. Christian, S.; Ahorn, H.; Novatchkova, M.; Garin-Chesa, P.; Park, J.E.; Weber, G.; Eisenhaber, F.; Rettig, W.J.; Lenter, M.C. Molecular cloning and characterization of EndoGlyx-1, an EMILIN-like multisubunit glycoprotein of vascular endothelium. J. Biol. Chem. 2001, 276, 48588–48595.
219. Doliana, R.; Mongiat, M.; Bucciotti, F.; Giacomello, E.; Deutzmann, R.; Volpin, D.; Bressan, G.M.; Colombatti, A. EMILIN, a component of the elastic fiber and a new member of the C1q/tumor necrosis factor superfamily of proteins. J. Biol. Chem. 1999, 274, 16773–16781.
220. Doliana, R.; Bot, S.; Mungiguerra, G.; Canton, A.; Cilli, S.P.; Colombatti, A. Isolation and characterization of EMILIN-2, a new component of the growing EMILINs family and a member of the EMI domain-containing superfamily. J. Biol. Chem. 2001, 276, 12003–12011.
221. Corallo, D.; Schiavinato, A.; Trapani, V.; Moro, E.; Argenton, F.; Bonaldo, P. Emilin3 is required for notochord sheath integrity and interacts with Scube2 to regulate notochord-derived Hedgehog signals. Development 2013, 140, 4594–4601.
222. Leimeister, C.; Steidl, C.; Schumacher, N.; Erhard, S.; Gessler, M. Developmental Expression and Biochemical Characterization of Emu Family Members. Dev. Biol. 2002, 249, 204–218.
223. Sanz-Moncasi, M.P.; Garin-Chesa, P.; Stockert, E.; Jaffe, E.A.; Old, L.J.; Rettig, W.J. Identification of a high molecular weight endothelial cell surface glycoprotein, endoGlyx-1, in normal and tumor blood vessels. Lab. Investig. 1994, 71, 366–373.
224. Lorenzon, E.; Colladel, R.; Andreuzzi, E.; Marastoni, S.; Todaro, F.; Schiappacassi, M.; Ligresti, G.; Colombatti, A.; Mongiat, M. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene 2012, 31, 3136–3147.
225. Colladel, R.; Pellicani, R.; Andreuzzi, E.; Paulitti, A.; Tarticchio, G.; Todaro, F.; Colombatti, A.; Mongiat, M. MULTIMERIN2 binds VEGF-A primarily via the carbohydrate chains exerting an angiostatic function and impairing tumor growth. Oncotarget 2016, 7, 2022–2037.
226. Noy, P.J.; Swain, R.K.; Khan, K.; Lodhia, P.; Bicknell, R. Sprouting angiogenesis is regulated by shedding of the C-type lectin family 14, member A (CLEC14A) ectodomain, catalyzed by rhomboid-like 2 protein (RHBDL2). FASEB J. 2016, 30, 2311–2323.
227. Noy, P.J.; Lodhia, P.; Khan, K.; Zhuang, X.; Ward, D.G.; Verissimo, A.R.; Bacon, A.; Bicknell, R. Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth. Oncogene 2015, 34, 5821–5831.
228. Braghetta, P.; Ferrari, A.; de Gemmis, P.; Zanetti, M.; Volpin, D.; Bonaldo, P.; Bressan, G.M. Overlapping, complementary and site-specific expression pattern of genes of the EMILIN/Multimerin family. Matrix Biol. 2004, 22, 549–556.
229. Hill, V.K.; Hesson, L.B.; Dansranjavin, T.; Dallol, A.; Bieche, I.; Vacher, S.; Tommasi, S.; Dobbins, T.; Gentle, D.; Euhus, D. et al. Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol. Cancer 2010, 9, 51.
230. Mongiat, M.; Marastoni, S.; Ligresti, G.; Lorenzon, E.; Schiappacassi, M.; Perris, R.; Frustaci, S.; Colombatti, A. The extracellular matrix glycoprotein elastin microfibril interface located protein 2: A dual role in the tumor microenvironment. Neoplasia 2010, 12, 294–304.
231. Bronisz, A.; Godlewski, J.; Wallace, J.A.; Merchant, A.S.; Nowicki, M.O.; Mathsyaraja, H.; Srinivasan, R.; Trimboli, A.J.; Martin, C.K.; Li, F. et al. Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat. Cell Biol. 2012, 14, 159–167.
232. Klenotic, P.A.; Zhang, C.; Lin, Z. Emerging roles of CCN proteins in vascular development and pathology. J. Cell Commun. Signal. 2016, 10, 251–257.
233. Jun, J.I.; Lau, L.F. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat. Rev. Drug Discov. 2011, 10, 945–963.
234. Mo, F.E.; Muntean, A.G.; Chen, C.C.; Stolz, D.B.; Watkins, S.C.; Lau, L.F. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol. Cell. Biol. 2002, 22, 8709–8720.
235. Babic, A.M.; Kireeva, M.L.; Kolesnikova, T.V.; Lau, L.F. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 1998, 95, 6355–6360.
236. Yu, Y.; Gao, Y.; Qin, J.; Kuang, C.Y.; Song, M.B.; Yu, S.Y.; Cui, B.; Chen, J.F.; Huang, L. CCN1 promotes the differentiation of endothelial progenitor cells and reendothelialization in the early phase after vascular injury. Basic Res. Cardiol. 2010, 105, 713–724.
237. Chintala, H.; Krupska, I.; Yan, L.; Lau, L.; Grant, M.; Chaqour, B. The matricellular protein CCN1 controls retinal angiogenesis by targeting VEGF, Src homology 2 domain phosphatase-1 and Notch signaling. Development 2015, 142, 2364–2374.
238. Hall-Glenn, F.; de Young, R.A.; Huang, B.L.; van Handel, B.; Hofmann, J.J.; Chen, T.T.; Choi, A.; Ong, J.R.; Benya, P.D.; Mikkola, H. et al. CCN2/connective tissue growth factor is essential for pericyte adhesion and endothelial basement membrane formation during angiogenesis. PLoS ONE 2012, 7, e30562.
239. Ivkovic, S.; Yoon, B.S.; Popoff, S.N.; Safadi, F.F.; Libuda, D.E.; Stephenson, R.C.; Daluiski, A.; Lyons, K.M. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003, 130, 2779–2791.
240. Liu, S.C.; Chuang, S.M.; Hsu, C.J.; Tsai, C.H.; Wang, S.W.; Tang, C.H. CTGF increases vascular endothelial growth factor-dependent angiogenesis in human synovial fibroblasts by increasing miR-210 expression. Cell Death Dis. 2014, 5, e1485.
241. Lin, Z.; Natesan, V.; Shi, H.; Hamik, A.; Kawanami, D.; Hao, C.; Mahabaleshwar, G.H.; Wang, W.; Jin, Z.G.; Atkins, G.B. et al. A novel role of CCN3 in regulating endothelial inflammation. J. Cell Commun. Signal. 2010, 4, 141–153.
242. Lin, C.G.; Leu, S.J.; Chen, N.; Tebeau, C.M.; Lin, S.X.; Yeung, C.Y.; Lau, L.F. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J. Biol. Chem. 2003, 278, 24200–24208.
243. Zhang, C.; van der Voort, D.; Shi, H.; Zhang, R.; Qing, Y.; Hiraoka, S.; Takemoto, M.; Yokote, K.; Moxon, J.V.; Norman, P. et al. Matricellular protein CCN3 mitigates abdominal aortic aneurysm. J. Clin. Investig. 2016, 126, 1282–1299.
244. Chen, P.C.; Cheng, H.C.; Wang, J.; Wang, S.W.; Tai, H.C.; Lin, C.W.; Tang, C.H. Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment. Oncotarget 2014, 5, 1595–1608.
245. Liu, H.; Dong, W.; Lin, Z.; Lu, J.; Wan, H.; Zhou, Z.; Liu, Z. CCN4 regulates vascular smooth muscle cell migration and proliferation. Mol. Cells 2013, 36, 112–118.
246. Chuang, J.Y.; Chen, P.C.; Tsao, C.W.; Chang, A.C.; Lein, M.Y.; Lin, C.C.; Wang, S.W.; Lin, C.W.; Tang, C.H. WISP-1 a novel angiogenic regulator of the CCN family promotes oral squamous cell carcinoma angiogenesis through VEGF-A expression. Oncotarget 2015, 6, 4239–4252.
247. Myers, R.B.; Rwayitare, K.; Richey, L.; Lem, J.; Castellot, J.J., Jr. CCN5 Expression in mammals. III. Early embryonic mouse development. J. Cell Commun. Signal. 2012, 6, 217–223.
248. Butler, G.S.; Connor, A.R.; Sounni, N.E.; Eckhard, U.; Morrison, C.J.; Noel, A.; Overall, C.M. Degradomic and yeast 2-hybrid inactive catalytic domain substrate trapping identifies new membrane-type 1 matrix metalloproteinase (MMP14) substrates: CCN3 (Nov) and CCN5 (WISP2). Matrix Biol. 2016.